Condition
Lung Disease, Interstitial
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
75.0%-12% vs avg
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
75.0%
-11.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
75% success
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Completed3
Terminated1
Trial Success Rate
75.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT02990286Phase 3CompletedPrimary
Evaluation of Efficacy and Safety of Rituximab With Mycophenolate Mofetil in Patients With Interstitial Lung Diseases
NCT00815711CompletedPrimary
Idiopathic Pulmonary Fibrosis Registry for Future Studies
NCT01361139Completed
Diagnosis of Cardio-Pulmonary Pathology Using Transthoracic Parametric Doppler (TPD)
NCT01618721Terminated
Detection and Characterization of Pulmonary Disease by Transthoracic Doppler (TTD)
Showing all 4 trials